Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	133.10M
Revenue (ttm)	67.64M
Net Income (ttm)	-116.05M
Shares Out	21.19M
EPS (ttm)	-5.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	617,577
Open	5.84
Previous Close	5.86
Day's Range	5.72 - 6.31
52-Week Range	5.70 - 17.80
Beta	0.49
Analysts	Buy
Price Target	19.50 (+210.51%)
Earnings Date	Feb 5, 2025

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA
• Website: https://www.enanta.com

Financial Performance

In 2024, Enanta Pharmaceuticals's revenue was $67.64 million, a decrease of -14.61% compared to the previous year's $79.20 million. Losses were -$116.05 million, -13.28% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for ENTA stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 210.51% from the latest price.

Price Target

$19.5

(210.51% upside)

Analyst Consensus: Buy